arrow
C

Christian Koenecke

Hannover Medical School
H指数:42
被引数:6,228

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lung transplantation after allogeneic hematopoietic stem cell transplantation: a study from the Transplant Complications Working Party of the EBMT

同种异基因造血干细胞移植后的肺移植:EBMT移植并发症工作组的研究

2026-10-260
PRE
Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome
Leukemia
IF13.4
2026-08-310
OA
Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124

更正:Pourroy等人。各年龄段大剂量甲氨蝶呤:安全性、有效性和欧洲HDMTX登记研究的结果。Cancers 2026, 18, 124

Cancers
IF4.4
2026-03-130
OAAI
Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland

德国和瑞士常规环境中,Brexucabtagene-autoleucel治疗复发/难治性套细胞淋巴瘤患者的疗效结果

2026-01-160
OAAI
High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry

全年龄段大剂量甲氨蝶呤:欧洲HDMTX登记研究的安全性、有效性与结局

Cancers
IF4.4
2025-12-310
OAAI
From Model to Man: Understanding Tregs' Dual Role in MASLD

从模型到人类:理解Tregs在MASLD中的双重作用

2025-10-090
OAAI
Chronic Graft-versus-Host disease trends over 30 years - a study by the EBMT transplant complications working party

慢性移植物抗宿主病30年趋势研究——EBMT移植并发症工作组的研究

2025-08-190
PRE
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study
LEUKEMIA
IF13.4
2024-11-190
PRE
Practice Patterns of SGLT2 Inhibitor Use in Stem Cell Transplantation and CART Cell Therapy: A Study from the EBMT Transplant Complications Working Party

SGLT2抑制剂在干细胞移植和CART细胞治疗中的使用模式:EBMT移植并发症工作组的研究

BLOOD
IF23.1
2024-11-050
PRE
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma

belantamab mafodotin与pembrolizumab在复发或难治性多发性骨髓瘤患者中的安全性和有效性

CANCER
IF5.1
2024-04-171
OAAI
Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study
2024-01-092
OAAI
ECP versus ruxolitinib in steroid-refractory acute GVHD - a retrospective study by the EBMT transplant complications working party

ECP与ruxolitinib在类固醇难治性急性GVHD中的比较-EBMT移植并发症工作组的回顾性研究

2023-12-112
OAAI
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial

CLDN6特异性CAR-T细胞联合扩增型RNA疫苗治疗复发或难治性实体瘤:BNT211-01期临床试验

2023-10-2370
OAAI
Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients
2023-10-0116
OAAI
BNT211-01: Interim results from a repeat dose escalation study of CLDN6 CAR-T cells manufactured with an automated process ± a CLDN6-encoding CAR-T cell-amplifying RNA Vaccine (CARVac)
2023-10-010
OAAI